Bamco Inc. NY Sells 5,682 Shares of Icon Plc $ICLR

Bamco Inc. NY cut its holdings in Icon Plc (NASDAQ:ICLR) by 0.8% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 684,941 shares of the medical research company’s stock after selling 5,682 shares during the quarter. Bamco Inc. NY’s holdings in Icon were worth $119,865,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in ICLR. Artisan Partners Limited Partnership lifted its position in Icon by 67.4% during the 2nd quarter. Artisan Partners Limited Partnership now owns 7,184,870 shares of the medical research company’s stock worth $1,045,039,000 after buying an additional 2,893,946 shares in the last quarter. Wellington Management Group LLP grew its holdings in Icon by 26.6% during the 3rd quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock worth $811,499,000 after acquiring an additional 975,268 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in Icon by 21.0% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,752,008 shares of the medical research company’s stock valued at $545,730,000 after acquiring an additional 650,379 shares in the last quarter. Invesco Ltd. raised its stake in shares of Icon by 11.1% in the third quarter. Invesco Ltd. now owns 3,427,630 shares of the medical research company’s stock worth $599,835,000 after acquiring an additional 341,637 shares during the last quarter. Finally, Principal Financial Group Inc. raised its stake in shares of Icon by 739.2% in the third quarter. Principal Financial Group Inc. now owns 3,277,293 shares of the medical research company’s stock worth $573,526,000 after acquiring an additional 2,886,755 shares during the last quarter. 95.61% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ICLR has been the topic of several research analyst reports. Rothschild & Co Redburn set a $100.00 price target on shares of Icon and gave the company a “neutral” rating in a research note on Tuesday, February 17th. Robert W. Baird set a $119.00 price objective on shares of Icon in a research report on Friday, February 13th. Zacks Research downgraded Icon from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 25th. BMO Capital Markets reissued a “market perform” rating and issued a $100.00 target price on shares of Icon in a research note on Thursday, February 12th. Finally, Jefferies Financial Group set a $135.00 target price on Icon and gave the stock a “buy” rating in a research report on Monday, February 23rd. Six equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Icon has an average rating of “Hold” and a consensus price target of $146.80.

Icon Price Performance

ICLR opened at $98.33 on Friday. The stock has a market cap of $7.94 billion, a P/E ratio of 13.31, a P/E/G ratio of 2.52 and a beta of 1.35. Icon Plc has a 12 month low of $66.57 and a 12 month high of $211.00. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The company has a fifty day simple moving average of $144.09 and a 200 day simple moving average of $165.46.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.